Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
about
von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studiesThe molecular characterization of von Willebrand disease: good in partsWhat have we learned from large population studies of von Willebrand disease?Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice.Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopeniaStandardization of von Willebrand factor propeptide: value assignment to the WHO 6th IS Factor VIII/von Willebrand factor, plasma (07/316).Genetic sequence analysis of inherited bleeding diseases.Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.Diagnostic approach to von Willebrand diseasevon Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesionThe B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner.New insights into genotype and phenotype of VWD.Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.Rapid discrimination of the phenotypic variants of von Willebrand disease.Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease.Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.Von Willebrand disease in the United States: a perspective from Wisconsin.Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.Accelerated clearance alone explains ultra-large multimers in von Willebrand disease VicenzaTranslational medicine advances in von Willebrand disease.von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.von Willebrand's disease diagnosis and laboratory issues.Advances in the diagnosis and management of type 1 von Willebrand disease.von Willebrand factor: at the crossroads of bleeding and thrombosis.Making a diagnosis of VWD.Clearance of von Willebrand factor.Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.Developments in the diagnostic procedures for von Willebrand disease.Current and emerging approaches for assessing von Willebrand disease in 2016.N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor.Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.C1272F: a novel type 2A von Willebrand's disease mutation in A1 domain; its clinical significance.Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.
P2860
Q26863636-F062B9D8-2C28-4126-B454-E4C11C9AF9D5Q26996413-D16B0D76-062A-4AF5-8BD5-99E5DC648F40Q30240214-BC2F90C6-597C-46EA-9889-729C966014EEQ30433859-4EE4BFDF-13FB-4D0B-AA57-FAF2C5FA7882Q33388822-BE81CFFB-2D8D-4000-AB98-2091153BD466Q34336999-5020220C-A34F-4561-B7EC-4EB23B6127C0Q34663589-8B36D61A-A82F-4FA7-B8FC-D4B80E1E77B5Q34923853-5C3CF3A9-6816-4EEA-9F5A-37A009CCFBBCQ35220634-87D948EF-2E72-4ECF-9B41-9B838C6E85E4Q36010217-9D2F468A-67D6-4C49-A105-112BB872D828Q36141868-E5D94133-D80A-482D-9FB8-B5E4A7B0C780Q36417697-F68EDE25-6E3C-4D3F-AEBC-03EAF0212789Q36510069-03E2BA81-9832-42D0-8D31-93572149FA0CQ36822738-49FF928F-CF19-4FBE-8E59-4697A7A9CEFFQ36920458-9B6EB660-2804-4CA0-8F86-448FEEEC06E8Q36920462-C0D8ECB2-BE9F-4BC6-9101-F1C4F27E2315Q36944971-0A3B19DE-CB42-43B3-AFA5-E86D2F04040AQ37078888-4A02399C-F9EF-420B-91CB-160D75D9CF2FQ37175593-9399BDB4-5249-44AC-A73F-D4E12E975AD9Q37253917-79A76D17-EE8D-4E08-AF5D-36DB7F221C05Q37259155-B1918090-0DAB-40F5-A952-92CD1BEB3F73Q37393334-5D9339DB-CE89-4982-B966-A11382614B03Q37602563-AF35E95B-F715-44BE-A85D-93392F22C4D6Q37635167-D4A75EE7-C1CF-430D-AA5E-A0189C9B3CF3Q37703427-03CD92E2-C330-4B82-B863-8CBE2DB3EE21Q37768874-00744BE7-8850-4D7C-B03B-87CE06EC0E07Q37842356-61490F37-01A1-4468-AE25-F4726C9771BEQ38000162-1018E9C9-D442-423A-936E-71566349CB13Q38066864-BE97C726-9717-4659-A617-EB095F390662Q38117738-30E1D861-4B4D-4FA9-9A93-509E03893A10Q38205952-740D8559-704C-46EA-8862-401A568B6739Q38682256-07FDBC77-4D3D-4FD3-804D-A381C3F65642Q38900004-61C15CB6-239C-4505-BE12-39C133ECE3F6Q39299024-18704FE8-750D-4F03-A696-CE96C6536284Q41174649-1D34A489-D0FF-4851-9FD9-F922E8AEA61BQ42664083-B6AD8F46-9EF6-4B42-9FF6-A77378232400Q42937413-A1B2FF15-DD96-4B8B-8BBE-0418CEAEE495Q43137286-CC23979C-FD7D-4749-9991-CB5360FFCD67Q44327207-47E590E3-95D9-4629-B575-C6D3F47FF454Q47793791-143947E6-E118-412D-9BA2-2F622C6A66E6
P2860
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@ast
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@en
type
label
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@ast
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@en
prefLabel
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@ast
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@en
P2093
P2860
P50
P1433
P1476
Identification of type 1 von W ...... nt of type 1 VWD (MCMDM-1VWD).
@en
P2093
Augusto B Federici
Claudine Mazurier
David Habart
Francesco Rodeghiero
Frank G H Hill
Giancarlo Castaman
Jenny Goudemand
Jorgen Ingerslev
P2860
P304
P356
10.1182/BLOOD-2007-09-110940
P407
P577
2008-03-14T00:00:00Z